NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery

Rhea-AI Summary

NVIDIA announced a strategic partnership with Novo Nordisk and DCAI to accelerate drug discovery through AI innovation. The collaboration centers on utilizing DCAI's Gefion supercomputer, powered by NVIDIA DGX SuperPOD, to create customized AI models for pharmaceutical research. Novo Nordisk will leverage NVIDIA's suite of tools including BioNeMo for AI-powered drug discovery, NIM and NeMo for agentic workflows, and Omniverse for simulation environments. The partnership aims to develop single-cell models for predicting drug responses and build biomedical language models using Novo Nordisk's scientific literature. The Gefion supercomputer is already supporting various healthcare initiatives in Denmark, including Teton's AI care companion project which has shown a 25% reduction in nightshift duties, and efforts to unite Danish health data into a national analysis platform.

Positive

• Partnership combines NVIDIA's AI expertise with Novo Nordisk's life sciences knowledge for faster drug development
• Access to advanced NVIDIA tools (BioNeMo, NIM, NeMo, Omniverse) enhances drug discovery capabilities
• Early trials of Teton's AI care companion showed 25% reduction in nightshift duties
• Gefion supercomputer enables unprecedented scale of pharmaceutical experiments

Negative

• None.

Leading Global Pharma Joins Danish Enterprises, Startups and Public Health Systems Using AI Factories to Improve Drug Discovery and Healthcare

PARIS, June 11, 2025 (GLOBE NEWSWIRE) -- NVIDIA GTC Paris at VivaTech — NVIDIA today announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. The work supports Novo Nordisk’s agreement with DCAI to use the Gefion sovereign AI supercomputer.

The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development and to apply advanced simulation and physical AI technologies.

“AI is essential for every industry, and there’s no other field that will benefit more from acceleration than drug discovery,” said Rory Kelleher, senior director of business development for life sciences at NVIDIA. “Working with Novo Nordisk, we’re advancing critical R&D applications with fundamental tools that can harness the full potential of generative and agentic AI to improve pharmaceutical development.”

Novo Nordisk Taps Advanced AI to Accelerate Innovation
DCAI’s Gefion supercomputer, powered by NVIDIA DGX SuperPOD™, provides Novo Nordisk an AI factory for running drug discovery and agentic AI workloads. Novo Nordisk will use NVIDIA BioNeMo™ for generative AI-powered drug discovery, NVIDIA NIM™ and NVIDIA NeMo™ microservices for building customized agentic workflows, and the NVIDIA Omniverse™ platform to create physically accurate simulation environments for developing physical AI applications.

Novo Nordisk researchers will focus on several AI research programs, including using single-cell models to predict cellular responses to drug candidates and structures, as well as designing models to build molecules with drug-like properties. The companies will also collaborate on tapping Novo Nordisk’s vast global scientific literature to build biomedical large language models, enabling researchers to uncover correlations between genes, proteins and diseases.

“By coupling NVIDIA’s accelerated computing platform and expertise with Novo’s deep expertise in life sciences research and development, we aim to build custom models that will aid our scientists in developing new medicines faster and more efficiently,” said Mishal Patel, senior vice president, AI and digital innovation at Novo Nordisk. “Gefion will allow us to run experiments at an unprecedented scale.”

Advancing Denmark’s Healthcare Ecosystem
DCAI owns and operates Gefion, Denmark’s flagship AI supercomputer. DCAI is helping lower the barrier for accessing advanced computing capabilities and enabling companies in Denmark to pursue research and development across healthcare and drug discovery.

“With Gefion’s computational power, we can tackle the toughest R&D challenges, with the ultimate goal of unlocking new possibilities for pharmaceutical research and development,” said Nadia Carlsten, CEO of DCAI. “By combining Gefion’s capabilities with NVIDIA’s expertise, our customers can accelerate innovation even further.”

Gefion has already been used by multiple customers to advance healthcare and drug discovery.

Teton, a Danish startup and member of the NVIDIA Inception program for cutting-edge startups, is tapping into Gefion to accelerate the development of its AI care companion for hospitals, using cameras and sensors installed in patient rooms to create real-time 3D digital twins. This allows nurses to monitor patients remotely and receive alerts about potential health issues. Teton’s technology aims to reduce workload burden on nurses — freeing them up for higher-value tasks — and improve patient care, with early trials showing up to a 25% reduction in nightshift duties.

Last month, DCAI announced that one of the first pharma companies to use Gefion will tap the supercomputer to accelerate drug discovery and development in neurological and psychiatric disorders. Another venture-backed company is using Gefion to accelerate the development of oral alternatives to widely used biologics and to target proteins that are currently difficult or impossible to drug with available compounds.

Gefion will also be used as part of an effort by Danish health organizations to unite previously siloed health data into a single national analysis platform, which will provide researchers with secure access to interconnected health data. Along with supercomputing resources, this will make it easier to analyze large datasets, identify disease patterns earlier and develop more personalized treatments.

Watch the NVIDIA GTC Paris keynote from NVIDIA founder and CEO Jensen Huang at VivaTech, and explore GTC Paris sessions.

About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in accelerated computing.

For further information, contact:
Janette Ciborowski
Enterprise Communications
NVIDIA Corporation
+1-734-330-8817
jciborowski@nvidia.com

Certain statements in this press release including, but not limited to, statements as to: working with Novo Nordisk, NVIDIA advancing critical R&D applications with fundamental tools that can harness the full potential of generative and agentic AI to improve pharmaceutical development; the benefits, impact, performance, and availability of NVIDIA’s products, services, and technologies; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing product and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

© 2025 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, NVIDIA BioNeMo, NVIDIA DGX SuperPOD, NVIDIA NeMo, NVIDIA NIM and NVIDIA Omniverse are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/92c0c3db-28ea-43c7-b0d5-9ac3b350edaf

FAQ

What is the purpose of NVIDIA's partnership with Novo Nordisk and DCAI?

The partnership aims to accelerate drug discovery through AI innovation, using DCAI's Gefion supercomputer to create customized AI models for pharmaceutical research and development.

What NVIDIA technologies will Novo Nordisk use in this collaboration?

Novo Nordisk will use NVIDIA BioNeMo for AI-powered drug discovery, NIM and NeMo for agentic workflows, and the Omniverse platform for simulation environments.

How will this partnership benefit NVDA stock and shareholders?

The partnership expands NVIDIA's presence in the pharmaceutical industry, demonstrating the versatility of its AI solutions and potential for revenue growth in the healthcare sector.

What results have been achieved using the Gefion supercomputer so far?

Early trials with Teton's AI care companion showed a 25% reduction in nightshift duties, and the supercomputer is being used to unite Danish health data and accelerate drug development for neurological disorders.

What specific AI research programs will Novo Nordisk focus on?

Novo Nordisk will focus on developing single-cell models to predict drug responses, designing models for drug-like molecules, and building biomedical language models using scientific literature.